MYC and hepatocellular carcinoma: We determined the IC50 against Dasatinib in a panel of 11 human HCC cell lines (Focus, Hep40, HLE, HLF, MHCC97H, Huh7, PLC/PRF/5, SK‐HEP1, SNU‐398, SNU‐449, and SNU‐475) and two mouse HCC cell lines derived from liver specific c‐Myc transgenic mice (HCC3‐4 and HCC4‐4).21 Consistent with a previous report,12 we found that Dasatinib showed a highly heterogeneous anti‐growth activity in HCC cells, with IC50 ranging from ~10 nmol/L to ~10 μmol/L (Table 1, Figure 1A and Figure S1).